Company Summary
Search
Home Page
 
Acasti Pharma Inc. 
Listed Company 
Current   Past  
Fiscal Year EndCompany StatusExempt Flag
February 29TradingN
Board of Directors
NamePosition
James S. Hamilton  Director of the Board
Jan D'Alvise  President & CEO
Janelle D'Alvise  Director of the Board
Jean-Marie (John) Canan  Director of the Board
Leendert H. Staal  Director of the Board
Roderick N. Carter  Director of the Board
Roderick Carter  Executive Chairman
Incorporation Locations
Inc. DateExpiry DateCountryRegionDescription
1/Feb/2002  Canada Quebec  
Exchange Filing Office
Location
Montreal Regional Service Office
Business Type(s)
Primary/SecondaryBusiness TypeDetails
Primary  Research and Development in the Physical, Engineering and Life Sciences  News Release April 29, 2015-Acasti is an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, also known as dyslipidemia. Because krill feeds on phytoplankton (diatoms and dinoflagellates), it is a major source of phospholipids and polyunsaturated fatty acids ("PUFAs"), mainly eicosapentaenoic acid ("EPA") and docosahexaenoic acid ("DHA"), which are two types of omega-3 fatty acids well known to be beneficial for human health. CaPre(R), currently Acasti's only prescription drug candidate, is a highly purified omega-3 phospholipid concentrate derived from krill oil and is being developed to help prevent and treat hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. 
Securities
SymbolSecurity NameMarketStatus
ACSTAcasti Pharma Inc.TSX VentureTRADING
Name HistoryFromTo
Acasti Pharma Inc.1/Feb/2002Present
Company Facts Reconciliation
SubjectDate Returned
Spring 2015 CFR Not Received
Associations
Auditing Firm:  KPMG LLP
Transfer Agent:  Computershare Investor Services Inc.
Latest Information
TypeDateTitle
News Releases  12/Apr/2017  NEWS RELEASE - ACASTI PHARMA TO PRESENT CAPRE OMEGA-3 BRIDGING STUDY RESULTS AT NATIONAL LIPID ASSOCIATION SCIENTIFIC SESSIONS[MARKETWIRE]
    NEWS RELEASE - ACASTI PHARMA PRÉSENTERA LES RÉSULTATS DE L'ÉTUDE DE TRANSITION DE L'OMÉGA-3 CAPRE AUX SESSIONS SCIENTIFIQUES DE L'ASSOCIATION NATIONALE LIPIDIQUE[MARKETWIRE]
    NEWS RELEASE - PROVIDES UPDATE ON CAPRE PHASE 3 DEVELOPMENT PRO[MARKET NEWS]
Bulletins  24/Mar/2017  Convertible Debentures
Meetings and Public Filings  Information on financial statements, public filings and corporate meetings for all Canadian public companies can be found at www.sedar.com
Property Locations
(not available)

* Historical Data